Chocolate delights | Software delays | Scientific excellence
An encouraging update from the French named but UK created chocolatier lifts its share price, but the valuation looks very rich to us. Elsewhere, a scientific instrument specialist continues to impress while a software group focused on the US healthcare market was more cautious. Read on here for the latest news from AIM.
Craneware: recovery taking longer than anticipated Craneware (AIM: CRW), the market leader in Value Cycle solutions for the US healthcare market, issued a somewhat disappointing trading update for the six months ending 31 December 2022. Group revenues in the period are expected to increase by 6% to approximately $84.7m (H1 FY22: $80.2m) with adjusted EBITDA up 8% to $25.5m. Software revenues remain robust and continue to recover from the pandemic, however, Professional services revenues, continue to be impacted and have remained at 8% of total revenues, rather than seeing growth back to the more typical level of 15%. Despite this,…